A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
Heath
Elisabeth I
EI
Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA. heathe@karmanos.org
Gaskins
Melvin
M
Pitot
Henry C
HC
Pili
Roberto
R
Tan
Winston
W
Marschke
Robert
R
Liu
Glenn
G
Hillman
David
D
Sarkar
Fazlul
F
Sheng
Shijie
S
Erlichman
Charles
C
Ivy
Percy
P
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy; D016227:Benzoquinones; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D047029:Lactams, Macrocyclic; D008297:Male; D015337:Multicenter Studies as Topic; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D012107:Research Design; D017828:Rifabutin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D016227:Benzoquinones; D047029:Lactams, Macrocyclic; D017828:Rifabutin; C112765:tanespimycin; D017346:Protein Serine-Threonine Kinases; D017430:Prostate-Specific Antigen